James Peyer Sells 25,000 Shares of Sensei Biotherapeutics (NASDAQ:SNSE) Stock

by · The Markets Daily

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE – Get Free Report) major shareholder James Peyer sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the sale, the insider owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Sensei Biotherapeutics Trading Down 6.4%

Shares of SNSE stock traded down $1.35 during trading hours on Monday, hitting $19.79. 65,516 shares of the company were exchanged, compared to its average volume of 205,528. Sensei Biotherapeutics, Inc. has a 52-week low of $5.60 and a 52-week high of $36.76. The stock has a market capitalization of $26.52 million, a price-to-earnings ratio of -0.14 and a beta of -0.25. The firm has a fifty day simple moving average of $26.41 and a 200 day simple moving average of $18.54.

Sensei Biotherapeutics (NASDAQ:SNSE – Get Free Report) last released its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). Sell-side analysts anticipate that Sensei Biotherapeutics, Inc. will post -2.77 EPS for the current year.

Analyst Ratings Changes

SNSE has been the subject of a number of recent research reports. Wall Street Zen lowered shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Loop Capital set a $50.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday. Leerink Partners initiated coverage on shares of Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective for the company. Citigroup initiated coverage on shares of Sensei Biotherapeutics in a research note on Friday, May 22nd. They issued a “buy” rating and a $55.00 price objective for the company. Finally, Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $46.25.

Get Our Latest Stock Analysis on SNSE

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SNSE. Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics during the 1st quarter valued at $22,758,000. Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics during the 1st quarter valued at $4,188,000. Bank of America Corp DE grew its position in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares in the last quarter. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Company Profile

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.

Read More